NPJ Vaccines最新文献_第8页

Author Correction: The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine. 作者更正：TAK-003的故事：影响四价登革热疫苗发展的关键决策。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-05-06 DOI: 10.1038/s41541-026-01471-3

Ian Escudero, Dieter Gniel, Shibadas Biswal, Eckhardt Petri, Gonzalo Perez, Mayuri Sharma, John Weil, Derek Wallace

引用次数: 0

Advances and future applications of immunocastration techniques: a comprehensive review. 免疫阉割技术的进展及未来应用综述。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-06 DOI: 10.1038/s41541-026-01474-0

Mingshuo Ji, Jiaqi Nie, Yue Chen, Jiahan Gang, Chao Dong, He Huang, Li-Ming Liu, Yongfei Zhou

引用次数: 0

Oral delivery of Trichinella spiralis antigens by yeast-derived β-glucan particles enhances anti-helminth immunity. 通过酵母衍生的β-葡聚糖颗粒口服旋毛虫抗原增强抗蠕虫免疫。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-05 DOI: 10.1038/s41541-026-01458-0

Zhina Liu, Yi Liu, Zijian Dong, Yaming Yang, Longjiang Tian, Xingyang Wang, Zhiyang Du, Xiaolei Liu, Xue Bai, Xuemin Jin

{"title":"Oral delivery of Trichinella spiralis antigens by yeast-derived β-glucan particles enhances anti-helminth immunity.","authors":"Zhina Liu, Yi Liu, Zijian Dong, Yaming Yang, Longjiang Tian, Xingyang Wang, Zhiyang Du, Xiaolei Liu, Xue Bai, Xuemin Jin","doi":"10.1038/s41541-026-01458-0","DOIUrl":"10.1038/s41541-026-01458-0","url":null,"abstract":"Intestinal helminth infections including Trichinella spiralis impose a heavy burden globally, yet effective oral vaccines are lacking due to antigen degradation and poor mucosal immunogenicity. This study develops an oral vaccine platform using yeast-derived β-glucan particles (GPs) to encapsulate T. spiralis antigens (Ag-GPs). These Ag-GPs demonstrated efficient antigen encapsulation, gastrointestinal stability, and excellent biocompatibility. In a mouse model, oral immunization with Ag-GPs was biocompatible and induced robust mucosal (SIgA) and systemic (IgG, IgE) antibody responses, while also stimulating dendritic cell maturation and T-cell activation. This immunization resulted in significant reductions in both adult worm and muscle larval burdens following T. spiralis challenge. Notably, the observed protective immunity strongly correlated with Dectin-1 receptor-mediated particle uptake and subsequent systemic immune activation. This work presents a promising dual-function platform, acting as both an adjuvant and delivery system, for developing oral vaccines against intestinal parasites.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice. 单价和多价OspA mRNA-LNP疫苗可诱导功能抗体并保护小鼠免受伯氏疏螺旋体感染。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-05 DOI: 10.1038/s41541-026-01451-7

Meredith B Finn, Graham Willsey, Carol Lyn Piazza, Luke Clendenen, Muskan Shrestha, Stephanie Soee You, Lingzhi Ma, Yukti Dhingra, Adrian R Laciak, Kevin A Uggowitzer, Joshua M Obiero, Grace Freeman-Gallant, Harini Natarajan, Shannon Green, Elham Pirayesh, Yen-Ting Lai, Sunny Himansu, Andrea Carfi, Linden T Hu, Nicholas Mantis, Obadiah Plante, Christina Dold

{"title":"Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice.","authors":"Meredith B Finn, Graham Willsey, Carol Lyn Piazza, Luke Clendenen, Muskan Shrestha, Stephanie Soee You, Lingzhi Ma, Yukti Dhingra, Adrian R Laciak, Kevin A Uggowitzer, Joshua M Obiero, Grace Freeman-Gallant, Harini Natarajan, Shannon Green, Elham Pirayesh, Yen-Ting Lai, Sunny Himansu, Andrea Carfi, Linden T Hu, Nicholas Mantis, Obadiah Plante, Christina Dold","doi":"10.1038/s41541-026-01451-7","DOIUrl":"10.1038/s41541-026-01451-7","url":null,"abstract":"Outer surface protein A (OspA) is a ~30 kDa lipoprotein displayed on the surface of Borrelia burgdorferi sensu lato, the etiological agent of Lyme disease. Here we report on the preclinical evaluation of OspA-encoding nucleoside-modified mRNA lipid nanoparticle (OspA mRNA-LNP) vaccines for the prevention of Lyme disease. Crystallographic and binding studies using a panel of transmission-blocking antibodies confirmed that the mRNA-encoded OspA serotype 1 (ST1) expressed in mammalian cells assumes its native structure and retains known protective epitopes. Immunization of mice with OspA ST1 mRNA-LNP elicited functional serum antibodies that promoted spirochete agglutination and complement-dependent borreliacidal activity in vitro. We also examined the impact of combining ST1 OspA mRNA with OspA STs 2-7, which are associated with predominant Borrelia genospecies in Europe (B. garinii, B. afzelii, and B. bavariensis). The additional six STs mRNA did not interfere with ST1 antibody titers and functionality. Finally, mice vaccinated two or three times with different dose levels of OspA ST1 mRNA-LNP or with the heptavalent mRNA vaccine were protected against B. burgdorferi infection in a tick-mediated challenge model. The monovalent and the heptavalent OspA mRNA vaccines (mRNA-1982 and mRNA-1975, respectively) are currently undergoing testing in a Phase 1 clinical trial (NCT05975099).","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13478462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Searching for immune correlates in Lassa vaccine development - workshop report. 在拉沙疫苗开发中寻找免疫相关因素-研讨会报告。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-04 DOI: 10.1038/s41541-026-01452-6

Trevor Brasel, Polina Brangel, Ifedayo Adetifa, Sylvain Baize, David Benkeser, Antonio Bertoletti, Alexander Bukreyev, Sue Charlton, Jakob Cramer, Robert W Cross, Miles P Davenport, Devy Emperador, Pierre Formenty, Dean Follmann, Robert F Garry, Peter B Gilbert, Sarah C Gilbert, Jimmy D Gollihar, Nicholas C Grassly, Marion Gruber, Swati B Gupta, Stephan Günther, Adam Hacker, Catherine Hoath, Michael R Holbrook, Marian Killip, Deborah King, Henshaw Mandi, Vincent J Munster, Christinah Mukandavire, Lisa Oestereich, Sylvanus Okogbenin, Paul Oloo, Slobodan Paessler, Stanley Plotkin, Laura Richert, David Safronetz, Erica Ollmann Saphire, Alessandro Sette, Amy Shurtleff, Julia Granerod, David Wohl, Marija Zaric, Katrin Ramsauer, Christine Dahlke

引用次数: 0

Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study. 感染消退后住院期间PCV13的免疫原性：疫苗研究。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-04 DOI: 10.1038/s41541-026-01453-5

Julie Mérindol, Irit Touitou, Coralie Cruzel, Barbara Seitz-Polski, Sophie Breaud, Johan Courjon, Fredéric Batteux, Marion Cremoni-Gauci, Vesna Brglez, Didier Payen, Michel Carles, Elisa Demonchy

{"title":"Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study.","authors":"Julie Mérindol, Irit Touitou, Coralie Cruzel, Barbara Seitz-Polski, Sophie Breaud, Johan Courjon, Fredéric Batteux, Marion Cremoni-Gauci, Vesna Brglez, Didier Payen, Michel Carles, Elisa Demonchy","doi":"10.1038/s41541-026-01453-5","DOIUrl":"10.1038/s41541-026-01453-5","url":null,"abstract":"Vaccination against Streptococcus pneumoniae in high-risk patients is crucial and hospitalization is a valuable opportunity. Adult patients hospitalized (>48 hours) for various infectious conditions and eligible for 13-valent pneumococcal conjugate vaccination from April 2021 to 2023 were included. The primary endpoint was the vaccine response rate (VRR) at least one month after vaccination. Of the 725 potentially eligible patients, 143 were included in the study. The most common comorbidities were diabetes mellitus (47%) and chronic cardiovascular disease (42%). VRR was acceptable at 46%, with a lower geometric mean concentration (GMC) of IgG in non-responders than in responders (1.27 µg/mL vs. 9.49 µg/mL, p < 0.001). In the multivariate analysis, the strongest negative predictor of VRR was a Charlson score of >3 (OR: 0.23 [0.06-0.81], p = 0.022). Vaccination within 48 hours after apyrexia (OR: 6.25 [1.85-20], p = 0.004) and the presence of diabetes (OR: 2.70 [1.05-7.14], p = 0.039) were independently associated with a better VRR. Hospitalization for acute infection should not be viewed as a barrier to vaccination but as an opportunity for optimized pneumococcal prevention after a short delay of apyrexia and should not be routinely postponed.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses. trac478佐剂重组N1神经氨酸酶流感病毒疫苗诱导平衡和广泛保护性免疫反应。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01456-2

Irene Hoxie, Kirill Vasilev, Jordan Clark, Hardik Amin, Garazi Peña Alzua, Disha Bhavsar, Eduard Puente-Massaguer, Karthik Siram, Kristopher Short, Rebekah Tee, David Burkhart, Jay T Evans, Florian Krammer

{"title":"A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses.","authors":"Irene Hoxie, Kirill Vasilev, Jordan Clark, Hardik Amin, Garazi Peña Alzua, Disha Bhavsar, Eduard Puente-Massaguer, Karthik Siram, Kristopher Short, Rebekah Tee, David Burkhart, Jay T Evans, Florian Krammer","doi":"10.1038/s41541-026-01456-2","DOIUrl":"10.1038/s41541-026-01456-2","url":null,"abstract":"Licensed influenza vaccines primarily target the variable hemagglutinin protein and provide inadequate cross-protection against mismatched or drifted viral strains. One promising approach to enhance the breadth of protection is to target the viral neuraminidase by incorporating a stable, recombinant neuraminidase protein with an effective adjuvant. We evaluated an intramuscular recombinant neuraminidase vaccine (N1-MPP) adjuvanted with a lipidated toll-like receptor (TLR)7/8 agonist (INI-4001), a synthetic TLR4 agonist (INI-2002), or both (TRAC-478) delivered as aqueous, liposomal, or squalene oil-in-water emulsions in mice. TLR agonists offset the Th2 bias of squalene emulsions and boosted antibody responses. Combining ligands synergistically amplified CD4⁺ immunity-increasing polyfunctional cytokine-producing T cells in lungs and spleen-while promoting Th1 cytokine production and antibody class switching. Aqueous and emulsion TRAC-478 N1-MPP induced high titers of cross-reactive, functional antibodies that exhibited strong ADCC activity and conferred protection in passive-transfer experiments. TRAC-478 N1-MPP vaccination protected against both H5N1 clade 1 and clade 2.3.4.4b viruses and recent H1N1 isolates, supporting the further development of N1-MPP adjuvanted with TRAC-478 emulsion as a stand-alone vaccine or potentially as a supplement for current vaccination regimens to improve protection against both seasonal influenza virus and strains with pandemic potential.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13342080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preexisting IgG forms immune complexes and links local thermal reactogenicity with immunogenicity in influenza vaccination. 在流感疫苗接种中，预先存在的IgG形成免疫复合物并将局部热反应性与免疫原性联系起来。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01477-x

Julia R Hirsiger, Silke Scarascia, Mike Recher, Glenn Bantug, Christoph T Berger

{"title":"Preexisting IgG forms immune complexes and links local thermal reactogenicity with immunogenicity in influenza vaccination.","authors":"Julia R Hirsiger, Silke Scarascia, Mike Recher, Glenn Bantug, Christoph T Berger","doi":"10.1038/s41541-026-01477-x","DOIUrl":"10.1038/s41541-026-01477-x","url":null,"abstract":"Pre-existing pathogen-specific antibodies shape vaccine outcomes, yet their impact on local reactogenicity and qualitative features of the immune response are not fully defined. In this prospective human cohort receiving seasonal influenza vaccination, high baseline hemagglutinin-specific IgG1 levels were associated with more pronounced local thermal responses at the vaccinated arm and greater vaccine-induced antibody levels. These IgG antibodies formed immune complexes with hemagglutinin, activated complement and enhanced Fc-receptor-dependent monocyte activation and phagocytosis in vitro, connecting pre-existing immunity to innate activation and local reactogenicity. Despite higher antibody levels and early plasmablast responses in subjects with strong thermal reactogenicity after vaccination, we observed lower avidity and hemagglutinin-inhibition capacity, suggesting extrafollicular responses. T cell responses were unaltered. These findings support a model in which pre-existing hemagglutinin-specific IgG may contribute to local thermal reactogenicity and qualitative features of the vaccine response through immune complex-mediated pathways, providing a framework for how prior immunity may shape human vaccine responsiveness.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13342333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid nanoparticle-encapsulated DNA vaccine prevented lung consolidation following heterologous influenza A virus challenge in pigs. 脂质纳米颗粒包裹DNA疫苗预防猪异源甲型流感病毒攻击后肺实变。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01473-1

The N Nguyen, Danh C Lai, Hung Q Luong, Kassandra Durazo-Martínez, Sushmita Kumari, Sarah Sillman, Phillip Gauger, Giao P Trinh, Hiep L X Vu

{"title":"Lipid nanoparticle-encapsulated DNA vaccine prevented lung consolidation following heterologous influenza A virus challenge in pigs.","authors":"The N Nguyen, Danh C Lai, Hung Q Luong, Kassandra Durazo-Martínez, Sushmita Kumari, Sarah Sillman, Phillip Gauger, Giao P Trinh, Hiep L X Vu","doi":"10.1038/s41541-026-01473-1","DOIUrl":"10.1038/s41541-026-01473-1","url":null,"abstract":"The substantial antigenic diversity of Influenza A virus (IAV) presents significant challenges to the development of broadly protective vaccines for swine. Moreover, pigs vaccinated with whole-inactivated virus or hemagglutinin (HA) subunit vaccines may experience more severe lung consolidation than non-vaccinated pigs when exposed to antigenically mismatched IAV strains, a phenomenon known as vaccine-associated enhanced respiratory disease (VAERD). We recently developed a lipid nanoparticle-encapsulated DNA (LNP-DNA) vaccine encoding the HA of IAV, which elicited robust immune responses following a single immunization and protected pigs against homologous IAV challenges. In this study, we compared the immunogenicity and protective efficacy between the HA protein-based vaccine and the HA DNA-based vaccine against an antigenically mismatched IAV strain in pigs. Neither vaccine induced cross-reactive hemagglutination inhibition (HI) antibodies nor prevented viral shedding in nasal secretions following heterologous challenge. However, while the HA protein-based vaccine exacerbated lung lesions compared to non-vaccinated controls, the HA DNA-based vaccine prevented the development of gross lung pathology. Transcriptomic analyses revealed distinct gene expression profiles between the two vaccine groups. These findings suggest that the LNP-DNA vaccine platform may offer a safer and more effective strategy for developing vaccines against IAV in swine.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13342099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies. 高亲和力不足以使B细胞被HIV广泛中和抗体激活。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01468-y

Chloe Rees-Spear, Olivia Payne, Emma Touizer, Alan Kennedy, Luke Muir, Peter Thomas, Alyssa Thomas DeCruz, Rachel A McKendry, Leo Swadling, Marit J van Gils, James E Voss, Laura E McCoy

{"title":"High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies.","authors":"Chloe Rees-Spear, Olivia Payne, Emma Touizer, Alan Kennedy, Luke Muir, Peter Thomas, Alyssa Thomas DeCruz, Rachel A McKendry, Leo Swadling, Marit J van Gils, James E Voss, Laura E McCoy","doi":"10.1038/s41541-026-01468-y","DOIUrl":"10.1038/s41541-026-01468-y","url":null,"abstract":"HIV broadly neutralizing antibodies (bnAbs) have been widely studied, and inducing a robust broadly neutralizing response remains a goal for many human vaccine studies. Much research focusses on creating higher affinity antigens to target bnAb precursors, however this ignores the role of non-neutralisers that are known to dominate HIV-specific responses. Furthermore, any effective vaccine will likely need to induce multiple bnAbs. Here, we question whether the previously postulated affinity ceiling of 10-9M limits bnAb induction above a certain affinity. Using adeno-associated virus (AAV)-mediated CRISPR-Cas9 engineering to express HIV-specific bnAbs and non-bNAbs in Ramos B cells, we investigate antigen-specific activation by BCRs of known binding/neutralization potency, epitope and affinity. We found that between different bnAb epitopes affinity was not predictive of activation. However, within individual epitopes and across non-bnAb epitopes, increased affinity results in increased activation. We propose that at activation-resistant bnAb epitopes, affinity is overruled to an extent by the physical BCR-antigen interaction, while more 'simple' and immunogenic non-bnAb epitopes are more heavily dependent on BCR affinity. These findings may have significant consequences for vaccine development, as a high affinity BCR-antigen interaction at an epitope with poor activation potential may be unsuccessful at participating in the humoral response.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13342595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0